What is Atai Life Sciences 's market cap?

Atai Life Sciences (ATAI) has a market capitalization of $2.7B and trades on NASDAQ.

Who are Atai Life Sciences 's competitors?

Atai Life Sciences 's key competitors include Axsome Therapeutics, Janssen Pharmaceutical, GH Research, and others. These companies compete in similar markets and product categories.

Who does Atai Life Sciences partner with?

Atai Life Sciences 's notable partners include Beckley Psytech Limited, COMPASS Pathways plc, Massachusetts General Hospital.

What subsidiaries does Atai Life Sciences have?

Atai Life Sciences 's subsidiaries include Recognify Life Sciences, Inc., IntelGenx Corp., EmpathBio, Inc..

Where is Atai Life Sciences headquartered?

Atai Life Sciences is headquartered in Germany and employs approximately 83 people. It has been publicly traded since 2021.

Atai Life Sciences

ATAI

Atai Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders with significant unmet needs.

Market cap

$2.65B+260%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$954.0KBeat by $736.9K EPS-$0.08Beat by $0.03

Read the full report

Next report

Aug 13, 2026 (In 2 weeks)

Revenue estimate$111.1K

EPS estimate-$0.10

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Axsome Therapeutics$12.3B+148%

Atai Life Sciences $2.7B+275%

GH Research$1.9B+105%

Alto Neuroscience$1.1B+1,195%

Neumora Therapeutics, Inc.$307.6M-16.6%

Enveric Biosciences$5.4M+73.3%

Silo Pharma, Inc.$334.0K-93.0%

By revenue growth

Axsome Therapeutics+63.9%

Johnson & Johnson+8.1%

By net margin

Johnson & Johnson21.48%-3.5pp

Axsome Therapeutics-26.59%+37.8pp

Profile

Atai Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders with significant unmet needs. The company utilizes a hybrid model of in-house drug discovery and strategic investments to advance a pipeline of psychedelic and non-psychedelic compounds. Their core value proposition centers on creating rapid-acting, durable, and commercially scalable therapies for conditions such as treatment-resistant depression and anxiety.

Competitive position

Atai is a leading player in the emerging psychedelic medicine space, distinguished by a diversified pipeline and a strategic investment approach in clinical-stage biotechs.

GeographiesUnited States, Germany, United Kingdom, European Union

Customer segmentsHealthcare providers, Psychiatric clinics, Specialty pharmacies

Business modelR&D intensive, Strategic investment, Intellectual property licensing

SuppliersContract research organizations, Specialized chemical suppliers, Academic research institutions

CustomersHospitals, Psychiatric treatment centers, Government and private health insurers

CountryGermany

Listed2021

Employees83.0

CEOSrinivas G. Rao

SectorHealthcare

IndustryBiotechnology

Websiteatai.life

FilingsSEC EDGAR

Questions, answered.

What is Atai Life Sciences 's market cap?: Atai Life Sciences (ATAI) has a market capitalization of $2.7B and trades on NASDAQ.
Who are Atai Life Sciences 's competitors?: Atai Life Sciences 's key competitors include Axsome Therapeutics, Janssen Pharmaceutical, GH Research, and others. These companies compete in similar markets and product categories.
Who does Atai Life Sciences partner with?: Atai Life Sciences 's notable partners include Beckley Psytech Limited, COMPASS Pathways plc, Massachusetts General Hospital.
What subsidiaries does Atai Life Sciences have?: Atai Life Sciences 's subsidiaries include Recognify Life Sciences, Inc., IntelGenx Corp., EmpathBio, Inc..
Where is Atai Life Sciences headquartered?: Atai Life Sciences is headquartered in Germany and employs approximately 83 people. It has been publicly traded since 2021.